The role of the potassium channel gene KCNK2 in major depressive disorder

Psychiatry Res. 2015 Feb 28;225(3):489-92. doi: 10.1016/j.psychres.2014.11.061. Epub 2014 Dec 9.

Abstract

Six single nucleotide polymorphisms (SNPs) of the KCNK2 gene were investigated for their association with major depressive disorder (MDD) and treatment efficacy in 590 MDD patients and 441 controls. The A homozygotes of rs10779646 were significantly more frequent in patients than controls whereas G allele of rs7549184 was associated with the presence of psychotic symptoms and the severity of disease. Evaluating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) dataset, we confirmed our findings.

Trial registration: ClinicalTrials.gov NCT00021528.

Keywords: KCNK2; Major depressive disorder; Psychotic symptoms.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Antidepressive Agents / therapeutic use
  • Depressive Disorder, Major / diagnosis
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / genetics*
  • Depressive Disorder, Treatment-Resistant / diagnosis
  • Depressive Disorder, Treatment-Resistant / drug therapy
  • Depressive Disorder, Treatment-Resistant / genetics*
  • Female
  • Genetic Predisposition to Disease / genetics
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic / genetics
  • Polymorphism, Single Nucleotide / genetics
  • Potassium Channels, Tandem Pore Domain / genetics*

Substances

  • Antidepressive Agents
  • Potassium Channels, Tandem Pore Domain
  • potassium channel protein TREK-1

Associated data

  • ClinicalTrials.gov/NCT00021528